The Norwegian Immunotherapy in Multiple Myeloma Study

Sponsor
St. Olavs Hospital
Study ID
NCT06855121
Status
Recruiting
Apply to this trial

Conditions

  • AL Amyloidosis
  • Myeloma Multiple
  • Plasma Cell Leukemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Teclistamab — DRUG
    Real-world use and dosing
  • Elranatamab — DRUG
    Real-world use and dosing
  • Ciltacabtagene Autoleucel — BIOLOGICAL
    Real-world use.
  • Talquetamab — DRUG
    Real-world use and dosing
  • Idecabtagene vicleucel — BIOLOGICAL
    Real-world use and dosing

Study Details

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

Key Dates

Start date
Jan 15, 2025
Status verified
Feb 2025
Primary completion
Jan 31, 2029
Completion
Dec 1, 2037

Study Design

Enrollment
400 participants (estimated)

Primary Outcome Measure

Determine the real-world overall response rates (ORR) [ Time Frame: From date of treatment start and until date of first documented progression or start of next line of therapy, whichever came first, assessed up to ten years. ]

Central Contacts

Related Studies